Relation Therapeutics Files for IPO Following $500M+ Drug Discovery Deals with GSK

On December 10, computational drug discovery startup Relation Therapeutics (hereinafter referred to as "Relation") announced two multi-project strategic collaborations with GlaxoSmithKline (GSK) to jointly develop multiple novel targets in the fields of fibrosis and osteoarthritis. The collaboration aims to leverage the latest machine learning technologies, combined with human genomics and patient-derived cellular data, to advance the development of innovative therapies.

According to the terms of the agreement, Relation will receive a $45 million upfront payment from GSK, which includes $15 million in equity investment, as well as up to $63 million in success-based milestone payments. In addition, across these two deals, the average sales milestone payment per target is $200 million, along with tiered royalties on net product sales.

Relation Therapeutics Inc. was founded in 2020 as a company focused on drug development and translation, with experimental and computational systems at its core, leveraging artificial intelligence (AI) technology to accelerate drug discovery. The company conducts drug discovery through active graph machine learning combined with single-cell analysis and deep clinical insights, pioneering the lab-in-the-loop platform that integrates active learning into every step of the drug discovery process, from predicting cell states to validating new targets.

Relation Therapeutics' machine learning platform can analyze massive amounts of biomedical data, uncover potential drug candidates, and predict their efficacy and safety. The company is currently focused on research related to bone diseases, developing drugs for osteoporosis, while also exploring projects in immunology and metabolic diseases.

In 2022, Relation Therapeutics became one of the four start-ups that gained access to NVIDIA's Cambridge-1 GPU supercomputer. Cambridge-1 represents decades of NVIDIA’s work in accelerated computing, artificial intelligence, and life sciences.

In March 2023, Relation Therapeutics identified osteoporosis as its first indication. The model developed by the company can help scientists understand the variant genes driving osteoporosis and how they affect gene and protein expression. Approximately 60% of the genes predicted by their model are novel genes associated with osteoporosis.

On March 14 this year, Relation Therapeutics completed a seed funding round totaling $35 million, led by Data Collective Venture Capital and NVIDIA. The funds will be used to advance the clinical process for the company’s osteoporosis product, expand into new business areas, and accelerate the company’s growth and progress in drug development projects.

David Roblin, CEO of Relation Therapeutics, stated that while significant progress has been made in the R&D process over the past decade, a deeper understanding of biology is still essential to truly advance the treatment of human diseases. This philosophy underpins Relation's R&D strategy, particularly in the study of diseases such as osteoporosis and fibrosis.

This collaboration focuses on the fields of fibrosis and osteoarthritis. Relation will lead observational studies to generate two unique functional disease datasets. Relation's Lab-in-the-Loop platform will analyze these datasets by integrating human genetics, single-cell multi-omics directly from human tissues, functional assays, and machine learning to discover new disease targets. This approach minimizes the risk of clinical failure by ensuring robust validation of targets before entering clinical trials.

Relation Therapeutics applies its platform to the fields of fibrotic diseases and osteoarthritis, with GlaxoSmithKline (GSK) holding global development and commercialization rights for any resulting targets. If these drug candidates reach the market, Relation Therapeutics will receive tiered royalties.

According to McKinsey statistics, the impact of generative AI on productivity could add trillions of dollars in value to the global economy. For the pharmaceutical industry, this technology could create $60 billion to $110 billion in economic value annually for the pharmaceutical and medical products sectors.

This collaboration is an important part of GSK's strategic layout in the AI + new drug development field. Since the beginning of this year, GSK has announced several cooperation agreements, reflecting its continuous investment and development in machine learning and biological research.

GSK's Layout in the AI Pharmaceutical Field Can Be Traced Back to 2017. In this year, GSK announced a collaboration with AI pharmaceutical company Exscientia, which will discover novel selective small molecules across multiple disease-related targets. At the same time, GSK also partnered with Insilico Medicine to identify new biological targets and molecules.

In February 2023, GSK partnered with Cytel, a U.S.-based biostatistics CRO, to combine algorithmic and cloud computing capabilities. Clinical development teams can use AI software to rapidly generate thousands of trial models for stress-testing uncertainties across large-scale clinical trials, including treatment effects and enrollment rates, while providing the ability to quantify scientific and commercial trade-offs through visualization.

In October this year, GSK announced an investment of £50 million in the University of Cambridge and Cambridge University Hospitals to kick off a five-year partnership aimed at advancing research and development in immune-related diseases. The collaboration will focus primarily on kidney and respiratory diseases. CG-TIC will leverage the complementary strengths of GSK and the University of Cambridge, adopting a "translational" approach centered on patients, integrating AI and machine learning to accelerate target discovery and new drug development.

MNCs generally have high expectations for the application of AI in drug development, viewing it as a key tool to improve efficiency, reduce costs, and accelerate the time to market for drugs. AI-driven drug discovery has become a key area of focus for MNCs. Not only GSK but also AstraZeneca, Takeda, Eli Lilly, Sanofi, AbbVie, and others are actively engaging in AI-driven drug discovery through self-built platforms, BD deals, and collaborative R&D efforts.

In October 2023, Sanofi and BioMap reached a strategic cooperation with a total financial value exceeding 1 billion US dollars. Based on BioMap's large life science model, the two parties will jointly develop leading models for biopharmaceutical discovery.

In March this year, AbbVie announced the acquisition of AI pharmaceutical company Landos Biopharma for a total of $212.5 million, at a 160% premium. Landos' core asset is the innovative investigational drug NX-13, used for treating ulcerative colitis, which has entered the phase II clinical stage.

Compared with the close cooperation between MNCs and AI companies, China's "AI + healthcare" sector started relatively late but has developed rapidly in recent years, with increasing attention across the entire field. Data shows that from 2018 to 2023, there were 292 financing events in China’s AI pharmaceutical industry chain, with a disclosed total financing amount of 82.247 billion yuan, making it one of the most favored areas in all biopharmaceutical financing sectors.

As AI technology continues to evolve and permeate, new drug development is being propelled forward step by step. Which companies will be the first to reap the benefits of AI-driven pharmaceuticals? Time will tell.